BioNTech SE
Biotechnology / ImmunotherapyFounded 2008- Updated July 2025
Reviewed by Swet Parvadiya
Last reviewed: July 2025
CorpDigest
BioNTech SE
Company History
Founded 2008 in Mainz, Rhineland-Palatinate, Germany
Last reviewed: 2025-07-15 · By Swet Parvadiya
BioNTech SE is burning through $2.5 billion annually in R&D expenses—82% of its total revenue—to fund the most aggressive oncology pipeline expansion in the company's 17-year history, while its primary revenue source, the Pfizer-partnered Comirnaty COVID-19 vaccine, collapses from a peak of $20.7 billion in 2021 to a guided $1.9-2.2 billion in 2025. This deliberate, high-stakes reinvestment strategy, funded by $19.0 billion in cash reserves accumulated during the pandemic, represents a make-or-break pivot from vaccine manufacturer to diversified oncology biopharmaceutical company. With more than 20 active Phase 2 and Phase 3 clinical trials, a $800 million acquisition of Chinese biotech Biotheus completed in February 2025, and first oncology launches targeted for 2026, BioNTech is racing against its own cash burn rate to validate a pipeline that the market currently values at approximately zero, as evidenced by a price-to-book ratio of 1.0 and a stock price that has declined 80% from its 2021 peak.
Prof. Ugur Sahin, M.D. is the Co-Founder, Chief Executive Officer, and Chair of the Management Board of BioNTech SE. Born in Turkey and raised in Germany, Sahin trained as a physician and immunologist, completing his medical doctorate at the University of Cologne with a focus on cancer immunotherapy. He held academic positions at Saarland University Medical Center, the University of Zurich, and the University of Mainz, where he established a research group in 2000 and became a professor of experimental oncology in 2006. In 2001, he co-founded Ganymed Pharmaceuticals with Ozlem Tureci and Christoph Huber, developing zolbetuximab for gastric and esophageal cancers. Ganymed was acquired by Astellas Pharma in 2016 for over $436 million after demonstrating significant overall survival benefit in a randomized clinical trial. Sahin launched BioNTech in 2008 to pursue individualized cancer immunotherapies based on mRNA technology, and in January 2020—weeks before the WHO pandemic declaration—he initiated 'Project Lightspeed' to develop an mRNA vaccine against SARS-CoV-2, leveraging two decades of platform development. Under his leadership, BioNTech developed the world's first approved mRNA medicine (Comirnaty) and is now pivoting the company toward oncology with over 20 active late-stage clinical trials. Sahin holds a minority interest in the listed company and has consistently emphasized that economic success is secondary to the scientific mission of improving patient outcomes. He is married to co-founder Ozlem Tureci.
Prof. Ozlem Tureci, M.D. is the Co-Founder, Chief Medical Officer, and Member of the Management Board of BioNTech SE. A German physician and immunologist with Turkish roots, Tureci trained at Saarland University Medical Center where she met and later married Ugur Sahin in 2002. Her clinical practice in oncology provided the foundational insight for BioNTech's mission: that the genetic heterogeneity of tumors—less than 3% similarity between patients with the same cancer type—was the root cause of treatment failure for standardized therapies. Tureci co-founded BioNTech in 2008 to develop individualized immunotherapies that could address this heterogeneity, initially focusing on mRNA-based cancer vaccines. She has led the clinical development strategy for all BioNTech programs, from the early cancer vaccine trials through the COVID-19 vaccine development and now the oncology pipeline pivot. As Chief Medical Officer, she oversees clinical trial design, regulatory strategy, and medical affairs. Tureci has been instrumental in establishing BioNTech's partnerships with Genentech/Roche, Pfizer, and other global pharmaceutical companies. She has received numerous honors including the German Future Prize (Deutscher Zukunftspreis) in 2021 alongside Sahin for the COVID-19 vaccine development. Tureci's public statements consistently emphasize the goal of translating research into survival for patients worldwide.
Dr. Christoph Huber is a scientific co-founder of BioNTech SE and was previously a co-founder of Ganymed Pharmaceuticals alongside Ugur Sahin and Ozlem Tureci in 2001. At Ganymed, Huber contributed to the development of zolbetuximab, a monoclonal antibody targeting CLDN18.2 for gastric and esophageal cancers, which demonstrated significant overall survival benefit in randomized trials and led to the company's acquisition by Astellas Pharma in 2016 for over $436 million. Huber's expertise in antibody development and translational oncology research informed BioNTech's early technology platform decisions, including the initial focus on multiple therapeutic modalities beyond mRNA. While maintaining a lower public profile than Sahin and Tureci, Huber's scientific contributions were instrumental in establishing the research culture and technical capabilities that enabled BioNTech's later success.
Prof. Ugur Sahin, Prof. Ozlem Tureci, and Dr. Christoph Huber founded BioNTech SE in Mainz, Germany, with initial backing from investors including the Strüngmann brothers, Michael Motschmann, and Helmut Jeggle. The company was established to develop individualized cancer immunotherapies based on mRNA technology, following two decades of academic research at the University of Mainz and Saarland University Medical Center.
Katalin Karikó, the biochemist whose pioneering work on nucleoside-modified mRNA would prove foundational to COVID-19 vaccine development, joined BioNTech as Senior Vice President. Her research on modifying uridine in mRNA to reduce immunogenicity while maintaining translational efficiency was critical to making mRNA therapeutics clinically viable.
BioNTech completed its initial public offering on the Nasdaq Global Select Market under ticker symbol BNTX, raising capital as an emerging growth company and foreign private issuer. The IPO provided funding to advance the oncology pipeline and expand manufacturing capabilities, valuing the company at approximately $3.4 billion at pricing.
On January 25, 2020, Ugur Sahin launched 'Project Lightspeed' to develop an mRNA vaccine against SARS-CoV-2, weeks before the WHO pandemic declaration. In March 2020, BioNTech announced its collaboration with Pfizer Inc. to jointly develop, manufacture, and commercialize the COVID-19 vaccine, with Pfizer providing global infrastructure and BioNTech contributing the mRNA platform.
On December 2, 2020, the Pfizer-BioNTech BNT162b2 vaccine received emergency use authorization from the UK Medicines and Healthcare products Regulatory Agency, becoming the world's first approved mRNA-based medicine and the first COVID-19 vaccine authorized for widespread use. FDA authorization followed on December 11, 2020.
For the fiscal year ended December 31, 2021, BioNTech reported total revenues of $20,684.6 million ($22.0 billion), with net profit of $11,218.8 million and diluted earnings per share of $43.20 ($46.87). The company delivered approximately 2.6 billion doses of Comirnaty to more than 165 countries and regions, including over 1 billion doses to low- and middle-income countries.
Total revenues declined to $18,868.6 million in 2022 as COVID-19 vaccine demand began normalizing, though the company still generated $15,643.8 million in gross profit share from the Pfizer collaboration. BioNTech began explicitly reinvesting pandemic profits into oncology pipeline expansion, increasing R&D expenses and headcount.
Total revenues fell to $4,162.7 million in 2023, a 78% decline from 2022, as COVID-19 vaccine demand collapsed and the virus entered endemic stages. The company maintained profitability with net profit of $1,014.0 million but began accelerating oncology investments, with non-COVID R&D expenses increasing to $1.60 billion.
For fiscal year 2024, BioNTech reported revenues of $2,998.7 million, a net loss of $725.2 million, and diluted loss per share of $3.02 ($3.00). R&D expenses surged 26% to $2.45 billion, with over 20 active Phase 2 and 3 oncology trials. The company maintained $19.0 billion in cash and securities while guiding 2025 revenues to $1.9-2.2 billion.
In November 2024, BioNTech signed an agreement to acquire Biotheus for $800 million upfront plus up to $150 million in milestones, securing full global rights to BNT327 (PM8002), a bispecific antibody targeting PD-L1 and VEGF-A. The acquisition, completed in February 2025, added a Chinese R&D hub with over 300 employees and an advanced biologics manufacturing facility.
In August 2025, BioNTech reached agreements with CureVac and GSK to resolve pending patent litigation regarding mRNA technology, agreeing to pay $370 million to GSK plus a 1% royalty on U.S. sales of mRNA COVID-19 and influenza products, with an additional $130 million and 1% rest-of-world royalty contingent on closing the CureVac acquisition.
BioNTech acquired Biotheus to secure full global rights to BNT327 (PM8002), a novel bispecific antibody combining PD-L1 checkpoint inhibition with VEGF-A neutralization. The acquisition also added an in-house antibody generation platform, bispecific ADC capabilities, and a Chinese R&D hub with over 300 employees and an advanced biologics manufacturing facility.
BioNTech acquired Gilead subsidiary Kite Pharma's cell therapy manufacturing facility in Marburg, Germany, to expand mRNA vaccine production capacity for the COVID-19 vaccine program. The facility was rapidly converted to GMP mRNA manufacturing.
BioNTech acquired InstaDeep, a Tunisian-British AI company specializing in deep learning and computational biology, to enhance its neoantigen prediction capabilities and drug discovery platform.